Our portfolio company Genialis, released Expressions version 3.0 to accelerate translational and clinical biomarker discovery. Expressions is the foundation of ResponderID, Genialis’ computational precision medicine technology suite for biomarker discovery. It serves as a secure repository of versioned experimental and clinical data and associated metadata that is consistently analyzed, annotated, and managed at scale.
The version launch of Expressions follows Genialis’ recent close of $13M Series A financing, announced in March 2023.
Expressions has been the software at the core of our work from the company’s earliest days, and today is the engine that runs the ResponderID platform. The new version makes identifying gene signatures easier and seeing how they behave across data sets. The system also helps ensure data is machine learning-ready, which is essential for us and our collaborators in translational and clinical R&D to build more innovative and accurate biomarkers.
said Rafael Rosengarten, Ph.D. CEO of Genialis.
Access their full press release here